vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -18.0%, a 29.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -4.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
ANIP vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $334.0M |
| Net Profit | $27.5M | $-60.0M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | -18.0% |
| Revenue YoY | 29.6% | -76.3% |
| Net Profit YoY | 367.5% | -170.6% |
| EPS (diluted) | $1.14 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $247.1M | $334.0M | ||
| Q3 25 | $227.8M | $382.0M | ||
| Q2 25 | $211.4M | $397.0M | ||
| Q1 25 | $197.1M | $316.0M | ||
| Q4 24 | $190.6M | $336.0M | ||
| Q3 24 | $148.3M | $396.0M | ||
| Q2 24 | $138.0M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $27.5M | $-60.0M | ||
| Q3 25 | $26.6M | $105.0M | ||
| Q2 25 | $8.5M | $87.0M | ||
| Q1 25 | $15.7M | $61.0M | ||
| Q4 24 | $-10.3M | $85.0M | ||
| Q3 24 | $-24.2M | $102.0M | ||
| Q2 24 | $-2.3M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | -11.4% | ||
| Q3 25 | 15.9% | 46.6% | ||
| Q2 25 | 6.6% | 37.8% | ||
| Q1 25 | 13.3% | 35.4% | ||
| Q4 24 | -2.3% | 38.4% | ||
| Q3 24 | -13.8% | 43.2% | ||
| Q2 24 | 3.7% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 11.1% | -18.0% | ||
| Q3 25 | 11.7% | 27.5% | ||
| Q2 25 | 4.0% | 21.9% | ||
| Q1 25 | 8.0% | 19.3% | ||
| Q4 24 | -5.4% | 25.3% | ||
| Q3 24 | -16.3% | 25.8% | ||
| Q2 24 | -1.7% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $1.14 | $-0.77 | ||
| Q3 25 | $1.13 | $1.36 | ||
| Q2 25 | $0.36 | $1.13 | ||
| Q1 25 | $0.69 | $0.78 | ||
| Q4 24 | $-0.45 | $1.06 | ||
| Q3 24 | $-1.27 | $1.29 | ||
| Q2 24 | $-0.14 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $64.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $468.0M |
| Total Assets | $1.4B | $4.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $285.6M | $64.0M | ||
| Q3 25 | $262.6M | $70.0M | ||
| Q2 25 | $217.8M | $50.0M | ||
| Q1 25 | $149.8M | $48.0M | ||
| Q4 24 | $144.9M | $103.0M | ||
| Q3 24 | $145.0M | $72.0M | ||
| Q2 24 | $240.1M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $540.7M | $468.0M | ||
| Q3 25 | $505.8M | $583.0M | ||
| Q2 25 | $436.8M | $570.0M | ||
| Q1 25 | $418.6M | $579.0M | ||
| Q4 24 | $403.7M | $650.0M | ||
| Q3 24 | $405.9M | $583.0M | ||
| Q2 24 | $455.8M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $1.4B | $4.2B | ||
| Q3 25 | $1.4B | $4.3B | ||
| Q2 25 | $1.3B | $4.3B | ||
| Q1 25 | $1.3B | $4.2B | ||
| Q4 24 | $1.3B | $4.2B | ||
| Q3 24 | $1.3B | $4.2B | ||
| Q2 24 | $920.8M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.37× | ||
| Q3 25 | — | 4.43× | ||
| Q2 25 | — | 4.44× | ||
| Q1 25 | — | 4.29× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $367.0M |
| Free Cash FlowOCF − Capex | $29.1M | $168.0M |
| FCF MarginFCF / Revenue | 11.8% | 50.3% |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $30.4M | $152.0M | ||
| Q3 25 | $44.1M | $86.0M | ||
| Q2 25 | $75.8M | $70.0M | ||
| Q1 25 | $35.0M | $59.0M | ||
| Q4 24 | $15.9M | $134.0M | ||
| Q3 24 | $12.5M | $79.0M | ||
| Q2 24 | $17.4M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $29.1M | $136.0M | ||
| Q3 25 | $38.0M | $75.0M | ||
| Q2 25 | $71.8M | $58.0M | ||
| Q1 25 | $32.5M | $52.0M | ||
| Q4 24 | $13.5M | $109.0M | ||
| Q3 24 | $7.7M | $71.0M | ||
| Q2 24 | $13.0M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 11.8% | 40.7% | ||
| Q3 25 | 16.7% | 19.6% | ||
| Q2 25 | 34.0% | 14.6% | ||
| Q1 25 | 16.5% | 16.5% | ||
| Q4 24 | 7.1% | 32.4% | ||
| Q3 24 | 5.2% | 17.9% | ||
| Q2 24 | 9.4% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 4.8% | ||
| Q3 25 | 2.7% | 2.9% | ||
| Q2 25 | 1.9% | 3.0% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 7.4% | ||
| Q3 24 | 3.2% | 2.0% | ||
| Q2 24 | 3.2% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 0.82× | ||
| Q2 25 | 8.87× | 0.80× | ||
| Q1 25 | 2.23× | 0.97× | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
